Phase IIa, double-blind, randomized, parallel, placebo-controlled trial to investigate the effect of PBF-680 in conjunction with usual medication in subjects with moderate to severe COPD.
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: PALOBIOFARMA SL
- Phase: II
- Execution start: 20/06/2022
- End of execution: 30/06/2023
- PI: BERNARDINO ALCAZAR NAVARRETE
